Update for investors of

LALPATHLAB

Dr.

PathLabs is currently trading at Rs. 2771.95, up by 31.85 points or 1.16% from its previous closing of Rs. 2740.10 on the BSE. The scrip opened at Rs. 2740.15 and has touched a high and low of Rs. 2794.40 and Rs. 2740.15 respectively. So far 5048 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 3645.00 on 10-Oct-2024 and a 52 week low of Rs. 2295.10 on 03-Mar-2025. Last one week high and low of the scrip stood at Rs. 2934.75 and Rs. 2730.60 respectively. The current market cap of the company is Rs. 23222.15 crore. The promoters holding in the company stood at 53.91%, while Institutions and Non-Institutions held 39.99% and 6.10% respectively. Dr. Lal PathLabs has expanded its genomics capabilities by adding Illumina’s NovaSeq X Series to its dedicated genomics division, Genevolve. With the integration of Illumina’s latest technology, the company can now deliver faster and more accurate genomic research insights. The NovaSeq X system features Illumina’s cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what’s possible in genetic sequencing. And its powerful technology allows users to unlock previously unimaginable discoveries and advancements. Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing (NGS), enabling the company to deliver actionable, AI-powered insights with greater speed and sensitivity. Dr. Lal Pathlabs is a provider of diagnostic and related healthcare tests and services in India.